Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA Trial in Progress

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Myotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data Analysis

AOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping

Burden of Duchenne Muscular Dystrophy in Patients with Mutations Amenable to Exon 44 Skipping (DMD44)

Phase 1/2 Trial Evaluating AOC 1020 Safety and Pharmacokinetics in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD): FORTITUDE Trial Design